|Bid||314.78 x 1300|
|Ask||321.29 x 900|
|Day's Range||320.30 - 327.78|
|52 Week Range||235.74 - 343.96|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||122.35|
|Earnings Date||Nov 29, 2021 - Dec 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||342.05|
Subscribe to Yahoo Finance Plus to view Fair Value for VEEVLearn more
Sponsors and contract research organizations (CROs) are accelerating digital transformation to advance toward patient-centric, paperless, and decentralized trials, according to the Digital Clinical Trials Survey Report conducted by Veeva Systems (NYSE: VEEV). The new global research shows life sciences companies are taking decisive action to improve operational challenges stemming from the rapid adoption of decentralized technologies during COVID-19, evolving to a study model that expands beyond
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Veeva Systems (NYSE: VEEV) today announced that the number of biotechs using Veeva Vault CDMS to run faster, more effective oncology trials more than doubled over the last year. Vault CDMS, a modern cloud application suite designed to manage clinical data for today's study builds, delivers the agility and efficiency needed to handle the demands of highly complex studies.